Replies to post #7156 on Momenta Pharmaceuticals, Inc. (MNTA)

[tinkershaw]

Reasonable to make inferences: "On the other hand if you "choose" cell host line based on certain parameters(to prove sameness) you will likely infringe on MNTA's patent at least for NEXT 20 years-2031(This patent is fresh out of the oven.filed in October 2011) "

It is a hypothetical, but far too tenuated to make any inferences that one could rely on. MNTA would need to become a litigation machine, like RMBS, worse...and this is far from clear, although a possible theory as to MNTA's future valuation.

I somehow doubt though that MNTA will be able to gate the FoB market like this into 2030...their strategy is to create biogenerics where everyone else creates biosimilars. Much better strategy if you ask me, much more reasonable and practical business plan than trying to patent the entire field against the likes of Novartis, Teva, Amgen, et al. That is a losing strategy in the end, much like the automatic windshield wiper.

Tinker

[iwfal]

"On the other hand if you "choose" cell host line based on certain parameters(to prove sameness) you will likely infringe on MNTA's patent at least for NEXT 20 years-2031(This patent is fresh out of the oven.filed in October 2011) "

Do you think the following scenario is likely:

a) Momenta, for whatever reason, chooses not to make a generic version of drug x

b) Company Z applies for a biogeneric version of drug x

c) Momenta sues them for patent infringement on a generic that is not hurting them in any way


Technically possible - but seems unlikely. The only scenario I can think of where that might happen is as part of a deal with big pharma. E.g. Big Pharma Company A signs an agreement with Momenta to launch 4 different biogenerics, but refrain from launching something that would compete with their own drug Z. Now a different company launches a biogeneric version of drug Z - and Big Pharma Company A uses Momenta's patent to stop the sale of the competitor to their drug Z.